Genocea Biosciences Announces $1.2 Million Grant For Malaria Vaccine Discovery

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genocea Biosciences, Inc. (NASDAQ: GNCA), a clinical-stage biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced the receipt of a $1.2 million grant from the Bill & Melinda Gates Foundation for the identification of protective T cell antigens for malaria vaccines.

The grant, which extends Genocea’s existing malaria collaboration with the Gates Foundation through 2015, supports comprehensive screening of the malaria proteome to identify targets of protective T cell responses. The Gates Foundation also invested in Genocea in its Series C funding round in 2012.

Help employers find you! Check out all the jobs and post your resume.